We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Regulatory News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

18 May 2022 12:06

RNS Number : 9686L
MGC Pharmaceuticals Limited
18 May 2022
 

MGC Pharmaceuticals Ltd.

PDMR Notification

18 May 2022

ASX, LSE: MXC

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Person Discharging Managerial Responsibilities (PDMR) has dealt with shares in MGC Pharma, and this notification is made in accordance the UK Market Abuse Regulations.

The shares the subject of this notice were issued to the PDMR in accordance with a Share Purchase Agreement executed by MGC Pharma and the owners of MediCaNL Inc in April 2021, with the issued shares being the final tranche of deferred consideration payable by MGC Pharma to the PDMR who was a shareholder of MediCaNL Inc.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Nadya Lisovoder

2

Reason for the notification

 

(a)

Position

 

Chief Medical Officer

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Full name of entity

MGC Pharmaceuticals Limited

 

Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Fully Paid Ordinary Shares

(b)

Identification Code (ISIN)

 

AU000000MXC6

(c)

Nature of transaction

Shares issued as consideration for a corporate entity acquired by the Issuer.

(d)

Currency

Price

Volume

Total

AUD

$0.067

6,721,179

450,319

Aggregated information

AUD

$0.067

6,721,179

450,319

(e)

Date of transaction

 

2022-05-13

(f)

Place of transaction

 

Outside a trading venue

 

--Ends--

 

Authorised for release by the Executive Chair, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au

MGC Pharmaceuticals Ltd

David Lim

Company Secretary

+61 8 6382 3390

info@mgcpharma.com.au  

UK Broker - Turner Pope

Andy Thacker

+44 203 657 0050

info@turnerpope.com

UK PR Advisors - Tavistock

Charles Vivian / Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBBGDUSGBDGDI
Date   Source Headline
3rd Apr 20247:30 amRNSSuspension - MGC Pharmaceuticals Limited
2nd Apr 20243:40 pmRNSChange of name to Argent BioPharma Limited
28th Mar 20249:12 amRNSPDMR Notification
28th Mar 20249:07 amRNSRefinancing of Convertible Securities Agreement
18th Mar 20248:23 amRNSResults of General Meeting
29th Feb 20249:36 amRNSHalf-year Report
19th Feb 20244:00 pmRNSUpdate - Application for Admission to Trading
13th Feb 202410:00 amRNSDispatch of General Meeting Documents
31st Jan 20247:30 amRNSDecember 2023 Quarter Activity Report
11th Jan 20249:54 amRNSDirector/PDMR Shareholding
22nd Dec 20239:09 amRNSCompany Update & Placing to Raise US$500,000
19th Dec 20237:57 amRNSArtemiCâ„¢ receives FDA Approval in Saudi Arabia
18th Dec 20239:06 amRNSNon-Deal Roadshow Presentation December 2023
1st Dec 20238:09 amRNSCorporate Update - Board and UK Adviser Changes
30th Nov 20239:08 amRNSResults of Shareholder’s Annual General Meeting
16th Nov 20231:51 pmRNSHolding(s) in Company
13th Nov 20239:15 amRNSHolding(s) in Company
9th Nov 202310:47 amRNSHolding(s) in Company
8th Nov 202311:52 amRNSHolding(s) in Company
8th Nov 202310:00 amRNSCapital Consolidation and US$7.9m Placement
1st Nov 202311:30 amRNSConsolidation and New Fund Raising
1st Nov 202311:03 amRNSMGC Secures US$7.9 Million In Firm Commitments
31st Oct 20239:32 amRNSDispatch of Annual General Meeting Documents
30th Oct 20237:16 amRNSSeptember 2023 Quarter Activity Report
25th Oct 20233:16 pmRNSResults of Shareholder’s General Meeting
9th Oct 202310:02 amRNSDate of AGM & Closing Date of Director Nominations
29th Sep 202310:40 amRNSAnnual Report for the year ended 30 June 2023
26th Sep 20237:36 amRNSLetter From the Managing Director
26th Sep 20237:35 amRNSDispatch of General Meeting Documents
12th Sep 20237:00 amRNSHolding(s) in Company
5th Sep 202312:34 pmRNSResults of Shareholder’s General Meeting
1st Sep 20237:30 amRNSChange of registry address notification
31st Aug 20238:44 amRNS30 June 2023 Preliminary Financial Report
30th Aug 20238:30 amRNSShare Purchase Plan Closed
15th Aug 20237:29 amRNSSPP – Extension of Closing Date
14th Aug 20237:00 amRNSPositive Pre-clinical Trial Results on CimetrA®
4th Aug 20239:10 amRNSDispatch of General Meeting Documents
3rd Aug 20232:23 pmRNSAustralian Prospectus & Share Purchase Plan
2nd Aug 202310:25 amRNSApplication for Admission to Trading
1st Aug 20238:56 amRNSMGC Pharma Launches Share Purchase Plan
31st Jul 20237:00 amRNSPermission for first import of Psilocybin
28th Jul 20239:05 amRNSResignation of Joint Company Secretary
28th Jul 20238:00 amRNSJune 2023 Quarter Activity Report and Cash Flow
21st Jul 202310:56 amRNSHolding(s) in Company
18th Jul 202311:41 amRNSPDMR Notification
14th Jul 20237:00 amRNS£0.7 million Fundraising
12th Jul 20237:00 amRNSFurther re AMC Places another $1M Order of ArtemiC
7th Jul 20237:00 amRNSAMC Places Another US$1M Order of ArtemiC™
3rd Jul 20237:00 amRNSReclassification of Psychedelic Compounds
30th Jun 20239:31 amRNSDetails of Company Address

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.